文献速递细菌感染、耐药与抗菌药物医院感染防控

替加环素联合方案对多重耐药鲍曼不动杆菌血流感染的协同作用

The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本研究以4株临床分离的多重耐药鲍曼不动杆菌(MDRAB)为对象,通过棋盘试验筛选替加环素与临床常用抗生素的协同组合,并用体外PK/PD模型及致死性血流感染小鼠模型验证。结果显示替加环素联合美罗培南协同作用最强(FICI≤0.5),高剂量替加环素联合美罗培南对替加环素敏感的MDRAB血流感染有优异协同疗效。

要点

  • 替加环素联合美罗培南对全部受试MDRAB菌株FICI≤0.5,协同作用最强
  • 高剂量替加环素联合美罗培南的协同作用见于替加环素敏感株,非敏感株未见
  • 小鼠模型中该联合使死亡率降至零,血、肝、肺、肾细菌载量显著下降(P<0.05)

核心结论

  • 高剂量替加环素联合美罗培南对替加环素敏感的MDRAB所致血流感染显示优异协同作用,对替加环素非敏感株则未见此效应,为临床治疗替加环素敏感MDRAB血流感染提供了有前景的选择。

研究设计与样本

  • 研究纳入4株临床分离的MDRAB菌株,采用棋盘试验计算替加环素与临床常用抗生素联合的FIC指数以筛选协同组合。
  • 通过模拟人体血清药物浓度-时间曲线的体外PK/PD模型评估协同效应,并用致死性血流感染小鼠模型在体内验证所选联合方案的协同疗效。

主要发现

  • 替加环素联合美罗培南协同作用最强,对所有MDRAB菌株FICI≤0.5,被选入后续实验。
  • 体外PK/PD模型中,高剂量替加环素联合美罗培南对替加环素敏感MDRAB显示优异协同活性,对非敏感MDRAB未见协同。
  • 替加环素敏感MDRAB诱导的致死性血流感染小鼠模型中,高剂量替加环素联合美罗培南组死亡率降至零,血、肝、肺、肾细菌载量显著下降(P<0.05)。

关键数值与推荐

  • 替加环素联合美罗培南对全部受试MDRAB菌株FICI≤0.5,判定为协同。
  • 高剂量替加环素联合美罗培南组小鼠死亡率降至零,血、肝、肺、肾细菌载量显著下降(P<0.05)。

临床怎么用

  • 对替加环素敏感的MDRAB血流感染,可考虑高剂量替加环素联合美罗培南作为治疗选择。
  • 替加环素非敏感的MDRAB血流感染不宜依赖该联合方案的协同作用,需另行评估。
  • 临床决策前应明确菌株对替加环素的敏感性。

局限性

  • 研究仅纳入4株临床分离MDRAB菌株,样本量有限。
  • 协同结论基于体外PK/PD模型与小鼠模型,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Bloodstream infections (BSIs) caused by MDR Acinetobacter baumannii (MDRAB) have become a serious threat. Tigecycline is one of the last-resort agents for MDRAB, but its monotherapy in BSIs is limited by insufficient serum exposure. Certain combination strategies can enhance anti-infection ability via a synergistic effect, thus achieving acceptable antimicrobial efficacy at a relatively lower concentration. Therefore, this study was conducted to explore tigecycline-based combinations with synergistic activity against MDRAB BSIs. METHODS: Four clinically isolated MDRAB strains were investigated. The FIC index (FICI) of tigecycline in combination with clinical common antibiotics was assessed to screen synergistic combination strategies through chequerboard assays. The synergistic effect was then evaluated by an in vitro pharmacokinetics/pharmacodynamics (PK/PD) model through simulating human drug serum concentration-time profiles. Finally, a lethal BSI murine model was used to verify the synergistic efficacy of selected combination strategies in vivo. RESULTS: Tigecycline combined with meropenem showed the strongest synergistic effect, with an FICI of ≤0.5 for all MDRAB strains, and was consequently selected for subsequent experiments. In the in vitro PK/PD model, high-dose tigecycline combined with meropenem showed excellent synergistic activity against tigecycline-susceptible but not against non-susceptible MDRAB strains. In a lethal BSI murine model induced by tigecycline-susceptible MDRAB, strong synergistic activity was verified in the high-dose tigecycline + meropenem group, with mortality reduced to zero and the bacterial load of blood, liver, lung and kidney significantly decreased (P < 0.05). CONCLUSIONS: High-dose tigecycline combined with meropenem displayed an excellent synergistic effect against BSIs caused by tigecycline-susceptible but not non-tigecycline-susceptible MDRAB, therefore providing a promising treatment choice for tigecycline-susceptible MDRAB BSIs in the clinic.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Zhang H, Liang B, Tan Z, et al. The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections. J Antimicrob Chemother. 2025. PMID: 41105424. doi:10.1093/jac/dkaf386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。